1	Factors affecting trust in clinical trials conduct: Views of stakeholders from
2	a qualitative study in Ghana
3	
4	Samuel Tamti Chatio ¹ *, John Kuumuori Ganle ² , Philip Baba Adongo ² , Ulrike Beisel ³ ,
5	
6	
7	¹ Department of Social Science, Navrongo Health Research Centre, Navrongo, Ghana
8	² School of Public Health, Colleague of Health Sciences, University of Ghana, Legon
9	³ Department of Geography, University of Berlin, Germany
10	
11	
12	
13	
14	
15	
16	
17	
18	*Corresponding Author: schatio@yahoo.co.uk
19	
20	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

Introduction: Globally, there are signs of declining public trust in science, especially in biomedical research. In Ghana, there are equally signs of public distrust in the conduct of biomedical research in Ghana. Typical examples are the unsuccessful conduct of the Ebola vaccine trial and the initial refusal of parents to allow their children to receive the recently piloted malaria vaccine in Ghana. Therefore, this study explored stakeholders' views on factors affecting trust in clinical trials conduct in Ghana.

Methods: This was a cross-sectional exploratory study using qualitative research approach.
Forty-eight in-depth interviews and Key informant interviews were conducted with
stakeholders. Purposive sampling technique was used to select participants. All the interviews
were recorded, transcribed and coded into main and sub-themes using QSR Nvivo 12 software
to aid thematic analysis.

Results: Overall, participants saw the need for the conduct of clinical trials in Ghana because clinical trial studies enable scientists to come out with effective medicines for the management of diseases. Pre-implementation factors such as inadequate stakeholder engagement, rumours and negative influence affected trust. Implementation factors such as perceived risks about clinical trials medicines, apprehensions on drawing and use of blood samples, poor informed consent administration and perceived no illness all negatively affected trust in clinical trials conduct.

40 Conclusion: Trust is a fundamental factor affecting a successful conduct of clinical trials. Thus,
41 there is need for collective efforts by all stakeholders including research institutions and clinical
42 trial regulatory bodies to take the issue of trust in clinical trials conduct seriously.

43

44 Keywords: Trust, clinical trials conduct, stakeholders' views, Ghana

45 Introduction

Globally, there are signs of declining public trust in science, especially in biomedical research 46 [1]. Evidence exists that scientists' dehumanization and exploitation of people in the name of 47 science led to suspicion and mistrust in the conduct of clinical trials [2]. The long list of 48 49 unethical conduct in biomedical research including the Tuskegee syphilis study of 1932 in the United States of America: the Guatemala experiments where about 1,308 innocent people were 50 intentionally infected with organisms of syphilis and gonorrhoea in 1946 and the Nazi doctors' 51 experiments subjecting prisoners to gruesome medical experiments where surgeries were done 52 without anesthesia have all contributed to undermine public trust in biomedical research [3,2]. 53 In Africa, there has been reported cases of public distrust in biomedical research such as the 54 55 boycott of the 2003 polio vaccination campaigns in Northern Nigeria because of a number of 56 factors, including the memory of a controversial trial of the antibiotic Trovan in 1996 and the 57 delayed polio eradication efforts in India and Democratic Republic of Congo [4,1].

58

In Ghana, there are equally signs of public distrust in the conduct of biomedical research. A 59 typical example is the Ebola Virus Disease (EVD) outbreak in West Africa, where Ghana was 60 selected to conduct EVD vaccine trial (Adenovirus 26 vectored glycoprotein/MVA-BN 61 (Ad26.ZEBOV/ MVA-BN) in the Volta Region was not successful because of public distrust 62 63 [5,6]. Closely related to this is the initial refusal by parents to allow their children to receive the recently piloted malaria vaccine in Ghana due to lack of trust [7]. The piloted malaria 64 vaccine is currently being implemented in selected regions in Ghana, thanks to better 65 community engagement and trust-building strategies deployed by the vaccine team. 66

67

Notwithstanding the vital role clinical trials play in ensuring disease prevention and qualityhealthcare delivery, lack of trust in the design and implementation of clinical trials could

undermine their successful implementation as was the case in the failed EVD vaccine trial in
Ghana [5]. Previous studies have reported a number of factors such as apprehensions about
drawing and use of blood samples, fear of possible harm and adverse effects of clinical trial
medicines negatively affected trust in clinical trials conduct [8,9].

74

While clinical trials have evolved and improved over time, producing significant advances in diagnosis, treatment and prevention, there are equally key challenges such as issues of transparency and trust [10,11]. The increasing signs of distrust in public institutions and biomedical science clearly suggest a need for examining factors affecting trust in clinical research especially in low-income settings. Therefore, this study explored stakeholders' views on factors affecting trust in the conduct of clinical trials in Ghana.

81

82 Methods/materials

83 Ethical considerations

The study protocol was reviewed and approved by the Ghana Health Service Ethics Review
Committee (GHS-ERC007/08/18). Written informed consent was obtained from participants.
To ensure confidentiality, codes were assigned to study participants and used on the transcripts.

88 Theoretical foundations of the study

Theories help to explain human behaviours and are therefore very important in designing and implementing research that seeks to address public health problem [12]. Thus, Kasperson's social amplification of risks framework (KSARF) has been adopted and used in the design of this study. Kasperson's risk framework explains the extent to which a particular risk event merges with psychological, social and cultural procedures to lessen feelings of risk [13]. The framework points out factors that influence risk perception and how risk events are interpreted

and communicated by social actors such as institutional stakeholders, traditional and social 95 media in ways that may increase or decrease public reactions to the risk event. According to 96 Kasperson, amplification occurs at two levels: in the transfer of information about the risk, and 97 in the response mechanisms of society. These socially built risk messages are consequently 98 interpreted and acted on by individuals based upon their personal characteristics and attitudes 99 [13]. Social amplification of risk theory is relevant to this work because it provides the 100 101 framework to analyse individual, community, socio-cultural and geopolitical level actors pertaining to trust in clinical trials and how messages about trial studies are communicated. 102

103

104 Study design

This was an exploratory study using qualitative research methods of data collection and analysis. In-depth interviews (IDIs) and Key informant interviews (KIIs) were conducted with participants between June and August, 2019. Qualitative research approach helps in capturing feelings, experiences and perceptions of participants on the issue under investigation [14]. Therefore, this approach was considered appropriate in this study because our study aimed at gaining deeper understanding on the role of trust and factors affecting trust in the conduct of clinical trials in Ghana.

112

113 Study site

114 This was a multi sited-study conducted in the republic of Ghana. Specifically, the interviews 115 were conducted in the Kassena-Nankana East Municipality and Kassena-Nankana West 116 District (Navrongo) of the Upper East Region, Kintampo in the Bono East Region, Hohoe 117 Municipality in the Volta Region and Accra in the Greater Accra region of Ghana.

118

120 Study participants

The study participants included community members (i.e people who have never taken part in clinical trials, those who qualified but have not shown interest to partake in clinical trials, people who were recruited into clinical trials and later dropped out and people who took part in at least 3 clinical trial studies) and community opinion leaders.

125

126 Clinical trial scientists who have led clinical trial studies in the three health research centres of the Health Research and Development Division of the Ghana Health Services (i.e the Navrongo 127 128 Health Research Centre, Kintampo Health Research Centre and Dodowa Health Research Centre), clinical trial monitors and regulatory bodies such as ethics committee members from 129 Navrongo Health Research Centre Institutional Review Board, Ghana Health Service Ethics 130 Review Committee and Ghana Food and Drug Authority members (FDA) were also included 131 in this study. Ghana's parliament is the legislative arm of government and its mandate include 132 promulgation of laws in addition to other oversight responsibilities. Therefore, the last category 133 of participants in this study comprised members of parliamentary select committee on health. 134

135

136 Sampling techniques

Purposive sampling method was used to select participants. Purposive sampling is where the
researcher selects study participants believed could provide appropriate information to help
answer the research questions [15].

140

141 Selection of participants

142 Community and opinion leaders in Navrongo

143 The Kassena-Nankana East Municipality (KNEM) and Kassena-Nankana West District144 (KNWD) fall under the research activities of Navrongo Health Research Centre (NHRC). The

centre was established in 1989 with the main aim of conducting high quality demographic and 145 health research to inform health policy. NHRC operates the Navrongo Health and Demographic 146 Surveillance System (NHDSS) in the two districts where fieldworkers routinely visit 147 households within the area to collect and update demographic characteristics of the people 148 including their experiences and involvement in clinical trial studies conducted in the area [16]. 149 The list of community members with this experience (i.e those who have participated in at least 150 151 3 clinical trials, those who qualified but did not show interest to take part in clinical trials and those who were recruited into clinical trials and later dropped out) was obtained using the 152 153 NHDSS data base. These individuals were visited by trained data collectors and those who were available and willing to take part in the study were included. 154

155

Regarding the selection of opinion leaders, two communities (one in KNEM and the other one in KNWD were selected for the study. Data collectors visited the selected communities and with the support of chiefs and elders, opinion leaders were identified. These opinion leaders were contacted and those who agreed after the purpose of the study was explained to them were interviewed.

161

162 Community members and opinion leaders in Hohoe

First, two communities were selected using purposive sampling method. Data collectors then visited these communities and with the support of sub-chiefs and elders in the two communities, list of some community members and opinion leaders was obtained. These people were contacted and those who agreed were included in the study.

167

168

170 Clinical trial scientists, monitors, regulators and members of parliament

171 Various processes were also followed to select these categories of participants into the study.
172 First, official letters were written to the heads of these institutions for their permission to recruit
173 people in their respective institutions into the study. When permission was obtained, the lead
174 author visited these institutions and with the support of the heads, a list of members was
175 obtained. These people were contacted and those who were available and willing to participate
176 in the study were included.

177

178 Training and data collection techniques

Two University graduate research assistants were recruited and trained by the lead author to 179 collect data. In-depth interviews (IDIs) and key informant interviews (KIIs) were the main data 180 collection methods used in this study. The KIIs were conducted with clinical trial scientists, 181 monitors and regulators while the IDIs were conducted with community members, opinion 182 leaders and MPs. Appointments were booked with participants before the interviews were 183 conducted. English language was used to conduct interviews with clinical trial scientists, 184 monitors, regulators and MPs. The interviews with community members and opinion leaders 185 were conducted in the main local languages (i.e Kasem, Nankani and Ewe) spoken in KNWD, 186 KNEM and Hohoe. With consent from participants, all the interviews were audio-recorded 187 using digital voice recorders. A total of 48 interviews (34 IDIs and 14 KIIs) were conducted. 188

189

190 Data management and analysis

191 Various steps were followed in the data management and analysis processes. In the first step, 192 recorded interviews were transcribed verbatim after repeatedly listening to them. Two people 193 with previous experience in qualitative research who could understand and speak the three local 194 languages and English were engaged to transcribe the recorded interviews. A codebook

containing the main themes and sub-themes was developed by the lead author and reviewed by 195 the second, third and fourth authors. The transcripts were then prepared and imported into QSR 196 Nvivo 12 software to facilitate data coding and analysis. The coding was done by the lead and 197 second authors. The coding process involved a critical review of each transcript and coding of 198 the data into themes. Thematic content analysis was used to analyse the data. The transcripts 199 were prepared and labelled using variables such as age, category of participant and study area. 200 201 This method did help the study team to compare views on the issues across the different categories during data interpretation. The results were presented as narrative and supported by 202 203 relevant quotes from the data.

204

205 **Results**

206 Participants' views on clinical trials conduct

Generally, participants in this study saw the need for the conduct of clinical trials. Clinical trials scientists, monitors and regulators reported that it was important for clinical trials to be conducted to generate new and effective medicines for the management of diseases especially infectious diseases. They added that clinical trials provided useful information on new innovations including vaccines, drugs and medical devices to facilitate the implementation of health policy decisions to improve provision of healthcare services.

There is need to conduct clinical trial because we have to provide adequate data on drugs and also to ensure that such drugs are able to treat illnesses they are meant for.

215 (KII-clinical trial scientist-07)

It is important for clinical trials to be conducted because it is through clinical trials, we are able to improve drug therapies, existing procedures or bring about new innovative procedures to address specific diseases in our country (referring to Ghana).

The conduct of clinical trials also helps inform policy decision to improve healthcare management. (KII-clinical trial regulator-06)

221

some community members and opinion leaders also held that the resistance of microorganisms 222 to some existing medicines (i.e vaccines and drugs) coupled with new emerging diseases, there 223 224 was the need to conduct clinical trials to find new ways or medicines to address these health 225 problems. Participants added that that since medicines were produced to be used by human beings, it was important for new medicines and other medical devices to be tested on people to 226 227 help determine the effectiveness of these medicines and devices before they were made available for the general public to use. 228 229 I think it is good to test them (referring to new medicines) on human beings. If you do not test the medicines, you will not know whether these medicines are good or not. (IDI-230 trial participant-01) 231

Clinical trials are good and I think it is very necessary to conduct clinical trial studies because looking at the situation at hand and you know microorganisms are becoming resistance to a lot of drugs and because there are new emerging diseases, there is need to conduct clinical trials to help address these health problems. (IDI-opinion leader-06)

237

Some MPs particularly reported that humans were used in other countries to test new medicines
and once Ghana belongs to the international community, the country was bound by the
principal of reciprocity to also contribute to the development of new medicines and science.
As one of them expressed it:

We are part of the international community and we benefit from medicines that have been approved through clinical trials conducted elsewhere. Thus, we (referring to

people in Ghana) are bound by the principal of reciprocity that if people are used to 244 test such drugs and we are now benefiting from the results of such research work, we 245 246 also have an obligation to contribute to the development of new drugs in this country. (**IDI-MP-03**) 247 248 Nonetheless, some participants had contrary views about the conduct of clinical trials to test 249 250 new medicines. These individuals perceived that it was risky for new medicines and other medical devices to be tested on human beings through clinical trial studies. They maintained 251 252 that an individual could take these trial medicines and develop serious health problems. ...Researchers giving me vaccine that is still going through trials, I have a little problem 253 about that; what if after giving me that vaccine and I get serious health problems and 254 *die?* (IDI-community member-03) 255 There are risks in taking trial medicines. Somebody may take these new drugs and die 256 instantly and so there are risks involved. (IDI-community member-refused to take 257 part-05) 258 259 Another participant said that taking part in clinical trials, researchers could reveal to people 260 261 some health conditions, which could affect them psychologically. As one community member 262 put it in the following quote: 263 For me, I do not like clinical trials because they (referring to biomedical researchers) may come and find a particular disease in me, which might rather make me think for 264 *the rest of my life.* (**IDI-community member-02**) 265 266 267

268 Factors affecting trust in clinical trials conduct

Participants highlighted various factors affecting trust in the conduct of clinical trials. These
have been categorized into pre-implementation and implementation factors and discussed
below:

272

273 **Pre-implementation factors**

274 Inadequate community engagement

Participants reported that inadequate community and stakeholder engagement to create awareness on clinical trials affected trust and participation in such studies. Participants believed that where people are not provided with the needed information on rationale of clinical trials through community engagement, it could create doubts and thereby negatively affecting trust in clinical trials conduct. Lack of stakeholders' engagement and education led to the failed ebola vaccine trial in Ghana according participants.


- 281 ...If you want to conduct clinical trial in Ghana people may want to know about the 282 rationale and benefits of such a trial to them as participants? If such information is not 283 given to people, they may have doubts on what the researchers are going to do and 284 once people are not sure of the need for that trial, they will not want to take part. Lack
- of information really affected the ebola vaccine trial in Ghana. (IDI-MP-02)
- 286The researchers did not educate the general public about the malaria vaccine. There287was no information such as how the vaccine came about, the side effects and all those

things. If you do not have information about these issues, how will you take part? (IDI-

288

289

community member-refused to take part-03)



them, stakeholders mistrust resulting from lack of information contributed to the failed ebola 293 vaccine trials in Ghana. 294

295For instance, the Ebola vaccine trial, there was so much noise about it and people who were even educated did not understand what the study was all about. When it 296 happens like that and the information gets out there to the community, everyone will 297 interpret it the way he/she wants and that brings about distrust. (KII-clinical trial 298 regulator-03) 299

The problem is that, majority of Ghanaians do not know what clinical trials are all 300 about and that is the underlining fact. People think that biomedical research is all about

laboratory work. When people are now invited to participate, then, they say why? You 302

303 want to use us as guinea pigs? (KII-clinical trials monitor-06)

304

301

Rumours and negative influence 305

Views expressed by participants in this study suggested that rumours about risks of clinical 306 trials affected trust and participation in such studies. Clinical trial scientists and regulators 307 reported that misinformation given to community members by some individuals or group of 308 people about perceived risks associated with the conduct of clinical trials negatively affected 309 trust in clinical trials conduct. They gave examples of how community members were 310 negatively influenced through audios, videos and WhatsApp messages that were circulated on 311 social media platforms and internet advising people not to take part in the planned ebola 312 vaccine trial and the piloted malarial vaccine in Ghana. 313

Community members were not having problem, but information and feedbacks that 314 were given to them by other people created doubts in their minds about the ebola 315 vaccine trial. For the malaria vaccine, I think everything was ready to go, only for an 316

317 independent group somewhere I think outside the country, to send WhatsApp messages
318 frightening everybody about the vaccine. (KII-clinical trial scientist-03)

- 319 *The current malaria vaccine trial, the problem came from outside the country because*
- *some people got videos from a certain lady who circulated them on WhatsApp painting*
- 321 *a bad picture about clinical trials. So, it is because of some of these campaigns that is*
- 322 *making people to have doubts.* (KII-clinical trial monitor-05)

323

324 Some community members also recounted instances where negative influence from individuals 325 through audio recordings had influenced their trust and decision to drop out of the piloted 326 malaria vaccine exercise in Ghana. As one of them put it:

- It was my spouse who refused for the child to receive the malaria medicine. My partner actually heard information from audio recording that researchers bring these medicines to test on us and see whether these medicines are good or not. In the audio, it was said that the malaria medicine was tested on human beings and some of them died, so, people should be careful with medicines that researchers bring into the
- 332 *country and ask people to take.* (**IDI-community member-dropped out-04**)

333

The issue of being used as guinea pigs and side effects were among the propaganda used by family members and friends to influence people negatively about clinical trial studies according to views shared by some opinion leaders.

Most at times safety is the main complaint. People who are against clinical trials said it is not safe, it will affect you and that is why researchers will not do it in Europe or America and they want to use our people as guinea pigs. (IDI-opinion leader-06)

Some educated people are polluting the minds of community members. These educated people will say do not volunteer to take part, don't you know that there are risks involved? So, whatever the educated person will tell the family members, they will

- 343 *believe it.* (**IDI-opinion leader-02**)
- 344

345 Implementation factors affecting trust in clinical trials conduct

346 Perceived risks and uncertainties

Some community members held that fear of risks such as side effects, uncertainties about treatment efficacy and in some cases, perceived death that could result from using some clinical trial medicines negatively affected trust and participation in clinical trials. They explained that experience of side effects from routine vaccinations people had received in the past contributed to low trust in clinical trials conduct. They gave examples on how people were scared of the piloted malaria vaccine exercise, which made them refuse their children participation in the exercise.

354 When the malaria vaccine came people were not ready to use it. They said that the

355 researchers are sitting there and collecting vaccines, injecting and killing children.

356 (**IDI-community member-refused to take part in trial-03**)

The fear of risks and site effects of trial drugs negatively influences trust of people. If trial participants are not certain of what they are taking, then there is fear and once there is fear, trust is low. If I am not sure of what the trial drug will do to me then, I will not trust and take it. (**IDI-MP-05**)

361

362 It was reported by one opinion leader that people had the perception that using clinical trial363 drugs could lead to impotency and also shortened an individual life span.

The other thing is that some people in our communities have the believe that some of these trial drugs could lead to impotency while others think it could reduce the number of years an individual will live on earth for using trial drugs. (**IDI-opinion leader-04**)

367

368 Drawing and use of biomedical samples

Drawing of biomedical samples such as blood during clinical trials was reported as another factor affecting trust in clinical trials conduct. According to participants, the inability of clinical trial scientists to explain to community members on reasons for drawing and use of blood samples led to doubts on what exactly these samples were used for. This created avenue for misconceptions by some community members that blood samples were drawn and sold by clinical trial scientist. These misconceptions invariably affected trust and individuals' interest in clinical trials especially studies that involved drawing of blood samples from participants.

376 Some community members think that researchers take blood samples and sell. There is 377 this woman, we all gave birth at the same period, when the research people came to 378 recruit us into the study, the spouse refused with the reason that researchers will only

379 *take blood from study participants and sell for money.* (**IDI-trial participant-05**)

380 I have a problem with drawing of blood because you would not know what researchers 381 are going to use the blood for. They (referring to researchers) will just take 382 participants' blood and they will not tell you what the blood will be used for and you 383 will now be thinking as to what exactly the researchers are going to do with the blood. 384 (IDI-community member-dropped out-04)

385

The issue of drawing blood samples from clinical trial participants and the perceptions that these samples were being used for spiritual purposes was also reported by some opinion leaders and MPs.

389 Some people normally refuse to give out blood because they belief that the blood is not
390 used only for research purpose. (IDI-opinion leader-03)

391 Sometimes, the fear is there and people believe that researchers use these blood 392 samples for juju (referring to spiritual purposes). Therefore, if researchers take blood 393 samples from somebody and they do not explain, the person will say oh, no, researchers 394 are taking my blood for spiritual purposes. (**IDI-MP-04**)

395

The apprehensions about drawing and use of blood samples and how that affects trust in the conduct of clinical trials was affirmed by clinical trial scientists, monitors and regulators as explained by one of them in the following quote:

399 Drawing of blood samples has been a very big problem and that makes clinical trial 400 very difficult to conduct. The reason is that blood is very significant in our local 401 communities because some people believe that life is in the blood and so, when you take 402 somebody's blood you have actually come in contact with the person's spirit. There is 403 also rumour that blood drawn from study participants is sold by researchers. (KII-404 clinical trial scientist-01)

405

406 **Poor informed consent procedures**

The views expressed by study participants suggested that poor or inappropriate informed consent administration could affect trust and participation in clinical trial studies. For instance, community members and opinion leaders reported that if clinical trial staff did not properly explain study procedures to potential participants, it could affect trust and their decision to participate in such studies.

In an attempt to get many people enrolled into a trial, they (referring to trial team) may not even explain the issues for the people to really understand and actually make an informed decision to be part of the study. Data collectors may give different information to the participants, which may not be in the consent form and that could lead to mistrust.

- 416 (IDI-opinion leader-Hoheo-06)
- 417 *I am wondering whether the fieldworkers do not know the issues or what? Because my*
- 418 spouse asked them questions and they could not answer. They rather asked my spouse
- 419 to go and see their bosses and that my spouse should just read the consent form and
- 420 *sign it for them.* (**IDI-community member-refused to take part-03**)
- 421

422 Similar sentiments were shared by clinical trial scientists on how poor informed consent 423 administration could significantly affect trust in clinical trials conduct. One of the clinical trial 424 scientists emphatically stated that serious attention was not given to informed consent by 425 clinical trial investigators in terms of how well data collectors were trained to administer 426 informed consent to participants prior to their recruitment into these studies.

As for informed consent, it is a huge problem and I do not know whether we should call
it informed again. Researchers are supposed to give study information and allow people
to ask questions regarding their fears that is not being done. So, informed consent is a
big problem affecting trust and I think we (referring to researchers) have not paid much
attention to it. (KII-clinical trial scientist-02)

432

433 Perceived no illness

434 Some community members did not understand why they should use trial medicines although

- they were not diagnosed to be sick or having a health problem. According to these
- 436 individuals, it was difficult to trust and take such medicines.

443	to take part-06)
442	in the name of helping research, I will not agree. (IDI-community member-refused
441	The issue is that I am not sick and yet you (referring to researchers) will bring medicine
440	will come and give me vaccine why? (IDI-community member-02)
439	I do not like clinical trials because as I am seated, I am very healthy then researchers
438	I do not really understand that. (IDI-community member-03)
437	I have a problem because I am not sick and yet researchers want to give me medicine!

444

445 **Discussion**

This study explored stakeholders' views on the conduct of clinical trials and factors affecting 446 trust in clinical trials conduct in Ghana. Generally, participants saw the need for clinical trials 447 to be conducted in Ghana. Apart from helping in the advancement of medical science, 448 449 participants said the conduct of clinical trials enables researchers to come out with new medicines for the management of diseases especially infectious diseases. Participants noted 450 that the resistance of microorganisms to existing medicines and the need to find new medicines 451 452 to replace old ones necessitates the conduct of clinical trial studies. Medicines are produced to be used by humans and therefore, it is important for these medicines to be tested on human 453 beings to ensure safety and effectiveness of new medicines before they are deployed for public 454 455 use. The views expressed by participants suggest that conducting clinical trials is necessary to ensure that medicines and other medical devices are safe and would not cause harm when 456 people use them. These findings corroborate previous studies that demonstrated that clinical 457 trials are conducted to determine the efficacy and safety of new medicines and treatments 458 [9,17]. 459

460

Community perceptions in biomedical research remain critical particularly in low- and middle-461 income countries [18]. Perception is a constructive process that allows individuals to make 462 inferences about what they see and think about a particular phenomenon, in this case the 463 conduct of clinical trials [19). Across sub-Sahara Africa, evidence suggests that the conduct of 464 clinical trials has largely been perceived to have positive impact on the lives of people 465 especially those who take part in these clinical trials largely because of benefits such as prompt 466 467 and free medical care [20]. Therefore, the extent to which these clinical trial studies are perceived to be beneficial could be one of the reasons why participants in this study saw the 468 469 need for the conduct of clinical trials.

470

Study participants mentioned several pre-implementation and implementation factors affecting 471 trust in the conduct of clinical trials. The findings revealed that inadequate stakeholder 472 engagement to create awareness about biomedical research largely affects trust in their conduct. 473 For instance, where people are not provided with required information on the need for clinical 474 trials to be conducted, they could form their own opinions about such studies. If these 475 perceptions happen to be negative, it could affect their trust in clinical trials conduct. It is not 476 surprising therefore that inadequate stakeholder engagement or education has been reported by 477 participants as one key factor affecting trust in clinical trials conduct. It has been largely 478 reported that lack of knowledge and understanding resulting from poor community engagement 479 480 negatively affects research activities [21].

481

To make matters worse, rumours and negative influence from friends and family members about perceived risks associated with clinical trials and the issue of being used as guinea pigs greatly affect trust especially, in low- and meddle-income countries. Misinformation about the rationale for clinical trials conduct could cause fear and doubts in the minds of people leading

to their mistrust in biomedical research. As proposed in Kasperson's social amplification of 486 risk framework, risk events are interpreted and communicated by social actors such as 487 institutional stakeholders as well as social media, and based on the interpretations attached by 488 these communicators, could increase or decrease trust in public health interventions such as 489 clinical trials [13]. These issues were widely reported in this study particularly by clinical trial 490 scientists. These findings also support earlier studies, which demonstrated that rumours about 491 492 risks in the conduct of clinical trials seriously affected trust and community participation in clinical trial studies [22, 8]. 493

494

The findings also revealed personal risk and fear as very important factors responsible for low 495 trust in the conduct of clinical trials. This is consistent with previous studies demonstrating that 496 people were not willing to take part in clinical trials because of perceived risks and some cases 497 uncertainty about clinical trial medicines [23]. The current study also found that uncertainty 498 about clinical trial medicines negatively affects trust and decision of people to get involved in 499 such studies. The possibility of new medicines not being effective and the perception that 500 taking medicine that is yet to be proven to be effective was viewed as being experimental in 501 nature and this has been an important factor negatively affecting trust in clinical trials conduct 502 according to views expressed by participants in our study. Other studies both in low and high-503 income countries have also reported perceived side effects and fear of possible harm as factors 504 505 affecting trust in clinical trials [24,23]. This means that the issue of fear of risks and its influence on trust in clinical trials conduct is not only a problem in low-and meddle-income 506 countries. Therefore, clearly communicating study procedures, risks and benefits to community 507 members especially potential clinical trial participants and giving them sufficient time to ask 508 questions and have their concerns addressed could improve and maintain trust in clinical trials 509 conduct [25]. 510

511

Furthermore, the views shared by a good number of participants in this study suggest that 512 people are suspicious that blood samples drawn from clinical trial participants may be sold by 513 clinical trial scientists or being used for other purposes instead of using it for the intended 514 purpose. This generated a mixed sense of anxiety and mistrust in the conduct of clinical trials. 515 The views expressed by both study participants and in literature suggest that the inability of 516 517 clinical trial scientists to educate community members on reasons for drawing blood samples from participants affects trust leading to doubts on the use of blood samples [26]. Closely 518 519 related to this is the issue of poor informed consent procedures prior to recruitment of people into clinical trial studies, which has also been described as key factor affecting trust. The 520 inability of data collectors to appropriately administer informed consent to participants during 521 clinical trial studies could largely be as a result of poor or inadequate training. Informed consent 522 administration is viewed as very vital in the conduct of clinical trials and depending on how 523 well clinical trial staff are able to engaged and explain study procedures to potential 524 participants, could positively influence their trust [27]. Clinical trial scientists must ensure that 525 data collectors are adequately trained to build their capacity and knowledge on how to 526 appropriately engage community members and explain clinical trials design and procedures 527 especially potential clinical trial participants during informed consent administration prior to 528 their recruitment into such studies. This is very important not only to help people to take 529 530 informed decisions, but also improve their trust in clinical trials conduct.

531

532 Study limitations

533 The major limitation is that since the study used purposive sampling, a non-probability534 sampling method to select participants to share their opinions on factors affecting trust in

clinical trials conduct in Ghana, the views expressed by participants are their personal viewsand may not necessarily represent views of the larger population.

537

538 Conclusion

The need for biomedical research to be successfully designed and conducted especially in low and middle-income countries where there is high outbreak of infectious diseases is very necessary. However, trust is a fundamental factor affecting a successful conduct of clinical trials as pointed out in our study.

543

Therefore, there is need for collective efforts by all stakeholders particularly academic 544 545 institutions, research institutions, Ministry of health, Ghana health services and civil society 546 organizations as well as clinical trial regulatory bodies to take the issue of trust and factors affecting trust in the conduct of clinical trials seriously. In addition, investment in national, 547 548 regional and community level trust-building activities through appropriate community and stakeholder engagement strategies is highly recommended to address the issue of mistrust 549 resulting from misconceptions people have in clinical trials conduct. Further, improved 550 informed consent procedures through effective training is critical to improving and maintaining 551 trust of community members in clinical trial studies especially in low- and meddle-income 552 553 settings such as Ghana.

554

555 Acknowledgement

The authors wish to thank all the study participants who shared their views with the study team
on the topic. We are also grateful to the research assistants (Mr. Isaac A. Ayaga and Miss.
Enyonam Duah) who helped us during data collection.

559 **References**

560	1.	UNICEF (2012) Levels & Trends in Child Mortality, Report: Estimates Developed by
561		the UN Inter-agency Group for Child Mortality Estimation. New York: United
562		Nations Children's Fund 2012.
563	2.	Ogungbure AA (2011) The Tuskegee Syphilis Study: Some Ethical Reflections.
564		Thought and Practice: A Journal of the Philosophical Association of Kenya. New
565		Series, 3(2), 75-92.
566	3.	Lantos JD (2014) Lessons from the controversy over the SUPPORT study. Archives
567		of Disease in Childhood. Fetal and Neonatal Edition, 99(1), F4-F5.
568	4.	Okonta P (2014) Ethics of clinical trials in Nigeria. Niger Med J, 55(3),188–94.
569	5.	Kummervold PE, Schulz WS, Smout E, Fernandez-Luque L, Larson HJ (2017)
570		Controversial Ebola vaccine trials in Ghana: a thematic analysis of critiques and
571		rebuttals in digital news. BMC Public Health, 17:642.
572	6.	AL JAZEERA (2015) "Ghana says locals used as 'guinea pigs' in Ebola trial". Al
573		jazeera report, 11/06/2015.
574	7.	Asante KP, Binka FN, Koram KA (2019) Malaria vaccine deployment in Africa:
575		focus on Ghana. Ghana Med J, 53(2): 90-91 doi:ttp://dx.doi.org/10.4314/gmj.v53i2.2
576	8.	Bouida W, Grissa MH, Zorgati A, Beltaief K, Boubaker H, Sriha A, et al., (2016)
577		Willingness to participate in health research: Tunisian survey. BMC Medical Ethics,
578		17:47.
579	9.	Chatio S, Baiden F, Achana FS, Oduro A, Akazili J (2016) Knowledge and
580		Perceptions about Clinical Trials and the Use of Biomedical Samples: Findings from a
581		Qualitative Study in Rural Northern Ghana. PLoS ONE, 11, 4.
582	10.	Hudson KL, Lauer MS, Collins FS (2016) Toward a New Era of Trust and
583		Transparency in Clinical Trials. JAMA, 316 (13). doi:10.1001/jama.2016.14668.

584	11. Ioannidis JPA (2016) Why	Most Clinical Research Is Not Useful? PLoS Med, 1	3(6),
585	e1002049.		

- 586 12. Venable JR (2006) The Role of Theory and Theorising in Design Science Research.
 587 Design Science Research in Information Systems and Technology, 1–18.
- 588 13. Kasperson RE, Renn O, Slovic P, Brown HS, Emel J, Goble R, et al. (1988). The
- social amplification of risk: a conceptual framework. Risk Analysis, 8, 177–87.
- 590 14. Creswell JW (2014) Research design: Qualitative, quantitative, and mixed methods
- 591approaches. Research Design Qualitative Quantitative and Mixed Methods
- 592 *Approaches*, 4th edition.
- 593 15. Creswell JW, Plano Clark VL (2011) *Designing and conducting mixed method*594 *research*. 2nd. Sage; Thousand Oaks, CA: 2011.
- 595 16. Oduro AR, Wak G, Azongo D, Debpuur C, Wontuo P, Kondayire F, et al. (2012)
 596 Profile of the Navrongo Health and Demographic Surveillance System. Int J
 507 Enidemial 41(4) 068 076
- 597 Epidemiol, 41(4), 968–976.
- 598 17. Joshi VD, Oka GA, Kulkarni AA, Bivalkar VV (2013) Public awareness and
 599 perception of clinical trials: Quantitative study in Pune. Perspectives in Clinical
- 600 Research, 4(3), 169–174.
- 18. Massawe IS, Lusingu JP, Manongi RN (2014) Community perception on biomedical
 research: A case study of malariometric survey in Korogwe District, Tanga Region,
 Tanzania. Public Health, 14:385.
- 19. Resinga PR, Davhan-Maselesele M (2017) A concept analysis of young adults;
- 605 Perception of HIV Counselling and Testing. Health SA Gesondheid, 22, 213-220.
- 20. Akazili J, Chatio S, Achana FS, Oduro A, Kanmiki EW, Baiden F (2016) Factors
- 607 influencing willingness to participate in new drug trial studies: a study among parents

608	whose children were recruited into these trials in northern Ghana. BMC Research
609	Notes 9:139

- 21. Varse F, Janani L, Moradi Y, Solaymani-Dodaran M, Baradaran HR, Rimaz S (2019)
 Challenges in the design, conduction, analysis, and reporting randomized clinical trial
 studies: A systematic review. Med J Islam Repub Iran, 33:37.
- 613 22. Zhang L, Chen K, Jiang H, Zhao J (2020) How the Health Rumor Misleads People's
- 614 Perceptionin a Public Health Emergency: Lessons from aPurchase Craze during the
- 615 COVID-19 Outbreakin China. Int. J. Environ. Res. Public Health; 17, 7213
- 616 doi:10.3390/ijerph17197213
- 617 23. Browne LJ, Rees CO, Delden JJM, Agyepong I, Grobbee DE, Edwin A, et al. (2018.
- The willingness to participate in biomedical research involving human beings in low-
- and middle-income countries: a systematic review. Tropical Medicine & International
 Health, DOI: 10.1111/tmi.13195.
- 621 24. Bell JAH, Forcina V, Mitchell L, Tam S, Wang K, Gupta AA, et al. (2018)
- 622 Perceptions of and decision making about clinical trials in adolescent and young
- adults with Cancer: a qualitative analysis. BMC Cancer, 18:629.
- 624 25. Kane S, Calnan M, Radkar A (2015) Trust and trust relations from the providers'
 625 perspective: the case of the healthcare system in India. Indian J of Med Ethics, 12(3),
- 626157-68.
- 627 26. Boahen O, Owusu-Agyei S, Febir LG, Tawiah C, Tawiah T, Afari S, et al. (2013)
- 628 Community perception and beliefs about blood draw for clinical research in Ghana.
- Transactions of The Royal Society of Tropical Medicine and Hygiene, 107, 261–265.
- 630 27. Horn EJ, Edwards K, Terry SF (2011) Engaging Research Participants and Building
- Trust. Genetic Testing and Molecular Biomarkers, 15(12), 839–840.
- 632